GHK-Cu serum, copper peptide, or injection? They are not one product.
The searched name can lead to a cosmetic serum, a 100 mg research vial, a compounded injection, a topical clinical trial, or even a different approved copper medicine. Start with the product category before comparing claims, prices, or evidence.
Four routes. Four different questions.
The same ingredient name does not carry one product's formulation, quality, safety, trial result, approval status, or price into another category.
GHK-Cu serum
A finished topical formula intended to beautify or alter appearance. Check the complete ingredient label, responsible company, directions, warnings, and exact claims. The ingredient name alone does not prove the finished formula, concentration, stability, absorption, or effect.
Read the cosmetic label and claimsGHK-Cu 100 mg vial
A laboratory research listing organized by exact chemical identity, nominal mass, seller, price, availability, and evidence route. It is not interchangeable with a cosmetic serum, compounded injection, clinical-trial product, or approved medicine.
Compare only like-for-like research listingsGHK-Cu injection
A route with a materially different risk and regulatory question. FDA says compounded injectable GHK-Cu may pose immunogenicity risks from aggregation and peptide-related impurities, with limited human data to inform safety considerations.
Verify the prescriber, pharmacy, formulation, and current FDA recordTopical clinical-trial gel
A sponsor-controlled study product in a registered Phase 2 wound-healing trial. The record estimates 60 participants and currently posts no results. A recruiting trial does not prove that a consumer serum or research vial works.
Follow the exact trial record and posted resultsOne complex, several names, and one dangerous look-alike.
Glycyl-L-histidyl-L-lysine
The three-amino-acid parent peptide. PubChem lists it separately from the copper complex.
Prezatide copper / copper tripeptide-1
The copper complex tracked by PubChem CID 71587328 and FDA UNII 6BJQ43T1I9.
Copper histidinate / ZYCUBO
A distinct FDA-approved copper replacement drug for pediatric Menkes disease. Its approval and label do not apply to GHK-Cu.
The questions behind GHK-Cu searches.
Every answer preserves the exact product and source boundary. This is educational reporting, not medical advice or a dosing guide.
What is GHK-Cu?
GHK-Cu is a copper complex of the three-amino-acid peptide glycyl-L-histidyl-L-lysine. PubChem lists the complex as prezatide copper, while FDA's substance record includes copper tripeptide-1, GHK copper, and GHK complex with copper as synonyms. The free GHK peptide and the copper complex are related identities, not interchangeable labels.
Is copper peptide the same as GHK-Cu?
Sometimes a label uses copper peptide as shorthand for copper tripeptide-1 or GHK-Cu, but copper peptide is not precise enough to identify every finished product. Confirm the ingredient name, complex, formulation, concentration if disclosed, and intended use. A serum label, a 100 mg research listing, and a compounded preparation can share familiar words without being equivalent products.
Is GHK-Cu serum FDA approved?
Cosmetics and their ingredients, except certain color additives, generally do not receive FDA premarket approval. So FDA approved is usually the wrong test for a cosmetic serum. The finished product still must be safe under labeled or customary conditions and properly labeled. Claims matter: FDA says intended use can cause a product marketed as a cosmetic to be regulated as a drug.
Is GHK-Cu injection FDA approved?
The FDA sources cited here do not identify an approved GHK-Cu injection. FDA instead lists GHK-Cu for injectable routes among nominated bulk substances that may present significant safety risks, citing potential immunogenicity from aggregation and peptide-related impurities and limited human safety data. An FDA substance identifier or seller listing does not establish drug approval.
Is there an approved GHK-Cu injection dosage chart?
No FDA-approved GHK-Cu drug label or injection schedule is established by the sources cited here. Online dosing charts should not be treated as approved instructions. They often omit exact identity, formulation, sterility, patient factors, monitoring, contraindications, and the FDA safety concerns attached to compounded injectable routes. This guide does not reproduce unapproved dosing instructions.
Does a GHK-Cu clinical trial prove that serum works?
No. NCT07437586 is a registered Phase 2 study of a specific topical GHK-Cu gel used on standardized acute wounds. It is recruiting, estimates 60 participants, and has no posted results. Its sponsor-controlled formulation, wound model, endpoints, and study procedures cannot be transferred to a consumer serum or research vial before results exist.
Is ZYCUBO the same as GHK-Cu?
No. ZYCUBO is copper histidinate, an FDA-approved copper replacement drug for pediatric patients with Menkes disease. GHK-Cu is prezatide copper, a complex containing the glycyl-L-histidyl-L-lysine tripeptide. The compounds, formulas, indications, evidence, and labels are different. The word copper does not make them substitutes.
Use the route that matches what is in front of you.
A useful comparison changes with the category. Do not apply the research-vial price board to a serum or interpret a cosmetic label as injection evidence.
Compare the finished cosmetic.
- Full ingredient label
- Responsible company and contact
- Exact claims and intended use
- Directions, warnings, and package size
- Concentration only when publicly supported
Compare the exact listing.
- GHK-Cu or prezatide copper identity
- Nominal mass and chemical form
- Current price and availability
- Seller and destination market
- Lot-linked evidence and its limits
Verify the drug route first.
- Approved product or compounded preparation
- Named prescriber and licensed pharmacy
- Exact formulation and current FDA record
- Patient-specific clinical oversight
- No borrowed cosmetic or research evidence
Searching for peptide skincare?
The peptides-for-skin guide decodes cosmetic ingredient families, finished-formula evidence, labels, serums, and moisturizers. It keeps topical products separate from research vials and injection claims.
Read the peptides for skin guide →No approved GHK-Cu injection chart is hiding in a cosmetic label.
FDA's substance record identifies prezatide copper but explicitly says a UNII does not imply regulatory review or approval. FDA's compounding safety page separately flags GHK-Cu for injectable routes because of potential aggregation, peptide-related impurities, immunogenicity, and limited human safety data.
A registered topical wound-healing trial is also not an injection label or consumer-serum endorsement. Follow NCT07437586 for its exact study status and future results.